Grifols, S.A.
Grifols, S.A.
Your view on GRFS
Overview
What the company does, where it operates, and who runs it.
About Grifols, S.A.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Jose Ignacio Abia Buenache
- Headquarters
- Avinguda de la Generalitat, 152, Barcelona, ES
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Jose Ignacio Abia Buenache
- Headquarters
- Avinguda de la Generalitat, 152, Barcelona, ES
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions.
The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins.
The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices.
The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals.
The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions.
The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Stock Data
Price chart, volume, and trading data.
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Grifols, S.A. from FRC's valuation model, read against the market price. GRFS last traded at $8.47, 15.8× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Grifols, S.A.. Starting points for Grifols, S.A.: P/E 15.8, EPS $0.72, beta 1.19 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Grifols, S.A.. Grifols, S.A. paid $0.11 per share over the last year — a 1.2% yield at the current $8.47 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Grifols, S.A.. Trailing twelve-month EPS for Grifols, S.A. stands at $0.72. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Analyst Ratings
- Strong Buy0
- Buy4
- Hold2
- Sell2
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | EUR 0.30 | EUR 0.27 | EUR 0.87 | EUR 1.07 |
| Low estimate | EUR 0.26 | EUR 0.27 | EUR 0.80 | EUR 1.00 |
| High estimate | EUR 0.33 | EUR 0.27 | EUR 0.95 | EUR 1.14 |
| No. of analysts | 1 | 1 | 1 | 2 |
| Year-ago EPS | EUR 0.29 | EUR 0.17 | EUR 0.57 | — |
| Growth | +2.6% | +53.9% | +53.3% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | EUR 2.07B | EUR 3.22B | EUR 7.71B | EUR 8.20B |
| Low estimate | EUR 2.07B | EUR 3.22B | EUR 7.66B | EUR 8.14B |
| High estimate | EUR 2.07B | EUR 3.22B | EUR 7.77B | EUR 8.27B |
| No. of analysts | 1 | 1 | 4 | 5 |
| Year-ago revenue | EUR 1.96B | EUR 1.73B | EUR 7.23B | — |
| Growth | +5.5% | +86.1% | +6.7% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Grifols, S.A.. Grifols, S.A. has reported as a listed company since 2011. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ABTAbbott LaboratoriesMedical - Devices$181.0B
- ADMAADMA Biologics, Inc.Biotechnology$3.0B
- BDXBecton, Dickinson and CompanyMedical - Instruments & Supplies$58.9B
- BIOBio-Rad Laboratories, Inc.Medical - Devices$10.0B
- HAEHaemonetics CorporationMedical - Devices$5.6B
- MRVIMaravai LifeSciences Holdings, Inc.Biotechnology$2.1B
- QDELQuidelOrtho CorporationMedical - Specialties$657M
- TECHBio-Techne CorporationBiotechnology$11.4B
More Drug Manufacturers - General companies
- PFE.NEPfizer Inc.NEO
- PTKFFPT Kalbe Farma Tbk.OTC$3.2B
- PTKFYPT Kalbe Farma Tbk.OTC$15M
- RHHBFRoche Holding AGOTC$390.8B
- RHHBYRoche Holding AGOTC$383.1B
- RHHVFRoche Holding AGOTC$386.4B
- SCLXScilex Holding CompanyNASDAQ$4M
- SCLXWScilex Holding CompanyNASDAQ$14M
- SNPHFSanten Pharmaceutical Co., Ltd.OTC$3.1B
- SNPHYSanten Pharmaceutical Co., Ltd.OTC$3.7B
- SNYSanofiNASDAQ$113.1B
- SNYNFSanofiOTC$115.1B
ETFs holding Grifols, S.A.
% of the fund
- IBBiShares Biotechnology ETF$11.1B in assets0.14%
- BINVBrandes International ETF$572M in assets1.43%
- KOMPState Street SPDR S&P Kensho New Economies Composite ETF$2.3B in assets0.13%
- BSMCBrandes U.S. Small-Mid Cap Value ETF$179M in assets1.73%
- SPDWState Street SPDR Portfolio Developed World ex-US ETF$41.0B in assets0.01%
- CGICCapital Group International Core Equity ETF$2.6B in assets0.04%
- APIEActivePassive International Equity ETF$1.1B in assets0.02%
- QQQSInvesco NASDAQ Future Gen 200 ETF$20M in assets0.70%
Largest holders first, then the funds most concentrated in GRFS.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Grifols, S.A., and how their positions are changing. At a $7.17B market value, institutional positions materially move Grifols, S.A.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Grifols, S.A.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Grifols, S.A.. Coverage tracks Grifols, S.A. within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Grifols, S.A.